HotMasterAn innovative Hot Start/Cold Stop technology for better ,,, PCR* results
r 72C for 5 seconds ...A 5.0 kb Phage Lambda target was amplified using Eppendorf HotMaster ... Primers and template: ...Forward Primer: GGCAAGCATAAGCACACAGA Reverse Primer: CAG...A 201 bp target in the human SRY gene (a single copy gene on the Y chr...
r>
72C for 5 seconds
Hold:
4C
Antibody-blocked Taq cycling conditions:
Initial Denaturation:
95C for 2 minutes
35 cycles:
94C for 1 second
55C for 1 second
72C for 5 seconds
Hold:
4C
Experiment 2: Processivity
A 5.0 kb Phage Lambda target was amplified using Eppendorf HotMaster
Taq DNA polymerase and Competitor A Hot Start DNA polymerase.
Primers and template:
Forward Primer: GGCAAGCATAAGCACACAGA
Reverse Primer: CAGCATAAGCGGCTACATGA
Template: 10 ng Lambda DNA
HotMaster Taq cycling conditions:
Initial Denaturation:
94C for 2 minutes
35 cycles:
94C for 45 seconds
61C for 30 seconds
65C for 5 minutes
Final extension:
65C for 5 minutes
Hold:
10C
Competitor A cycling conditions:
Initial Denaturation:
95C for 10 minutes
35 cycles:
94C for 45 seconds
61C for 30 seconds
72C for 5 minutes
Final extension:
72C for 5 minutes
Hold:
10C
Experiment 3: Sensitivity
A 201 bp target in the human SRY gene (a single copy gene on the Y chromosome)
was amplified using
'"/>
Source:
Page: All 1 2 3 4 5 6 7 Related biology technology :1.
Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
(Date:11/23/2009)...3/PRNewswire/--Frost&Sullivan,theGrowthPartner...tingleadershipandinnovationThursday,November19,200...theldinSanAntonio,Texas. ,, (Logo: http://www.n...eHealthcareInnovationAwardsaregiventocompaniesthat...nagementofhealthcare.Suchcompanieshaveshownsuccess...
(Date:11/23/2009)...re-FirstCall/--CornerstoneTherapeuticsInc.(Nasdaq:...quiring,developingandcommercializingsignificantpro...odayannouncedthatCraigA.Collard,PresidentandChiefE...atthe21stAnnualPiperJaffrayHealthCareConferenceat3...eHotelinNewYorkCity. ,, Aliveaudioandarchivedwe...
(Date:11/20/2009)...ies have an opportunity to take the lead in two sm...iversity of Valencia (UV), working together with t... fabric of the Spanish biotechnology industry. The...rs have more clout than those in English-speaking ...d plants has been overlooked by the leading countr...
(Date:11/20/2009)...ewswire-FirstCall/ -- Dendreon Corporation (Nasdaq...rug Administration (FDA) provided written acknowle...se Application (BLA) for PROVENGE® (sipuleuce... a Prescription Drug User Fee Act (PDUFA) date of ...reon,s amended BLA. Dendreon is seeking licensure...
Breaking Biology Technology:Excellence in Healthcare Innovation Recognized by Frost & Sullivan 2Excellence in Healthcare Innovation Recognized by Frost & Sullivan 3Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Spanish biotechnology should focus on food and plant sectors to be more competitive 2Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3...l 25 CV Therapeutics,Inc. (Nasdaq: CVTX ) today ...nded March 31, 2008., For the quarter ended March...9 million, or $0.53 per share. This compares to a ... the prior quarter ended December 31, 2007,and $55...er in 2007., For the quarter ended March 31, 2008...
...ntists and Collaborators Publish Study in Science,...bH, the,leading developer of RAFT intervention the...per in Science demonstrating a potential novel str...and other diseases by targeting,discrete sub-compa...nducted,by JADO scientists together with several a...
...lif., April 24 ,Exelixis, Inc. (Nasdaq: EXEL ) an...t and chief executive officer of Exelixis, will pr...ugged Conference at 3:40 p.m. ET/12:40,p.m. PT on ...s updates to,the company,s development pipeline an...ebcast and may be accessed in the Event,Calendar p...
Other Biology Technology:CV Therapeutics Reports 2008 First Quarter Financial Results 2CV Therapeutics Reports 2008 First Quarter Financial Results 3CV Therapeutics Reports 2008 First Quarter Financial Results 4CV Therapeutics Reports 2008 First Quarter Financial Results 5Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 2Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 3Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 4Sheep Anti-Salmonella Thomasville Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Drosophila Melanogaster Achaete protein Monoclonal Antibody, Unconjugated from Developmental Studies Hybridoma Bank
Rabbit Anti-OCT6 Polyclonal Antibody, Unconjugated from Abcam
...rk, Super-Small! Capture high-resolution chemilum...oc-It Imaging System. High-sensitivity camera is c...ound noise and wide dynamic range for high quality...cabinet provides optimum conditions for chemilumin...
Biology Products: